Viral Vector

© GettyImages/Dr_Microbe

Charles River looks to speed up viral vector manufacturing

By Jane Byrne

Charles River Laboratories International has launched a new AAV based platform that it claims has the capability to reduce time from process development to GMP by 55% and deliver a drug product in fewer than eight months.

Vibalogics Cuxhaven facility Germany © Vibalogics

Vibalogics adds capacity for virotherapy manufacturing in Germany

By Jane Byrne

Vibalogics, which was recently acquired by Swedish company, Recipharm, says the completion of its expansion project at its facility in Germany boosts capacity and further enhances its flexibility, minimizing time to clinic for customers.

Event inaugurating the new plant in Spain in June © VIVEbiotech

Special Edition: Meeting demand for viral vectors

VIVEbiotech looks to overcome challenges related to LVV production

By Jane Byrne

VIVEbiotech, a lentivirus-specialized contract development and manufacturing organization (CDMO) that produces vectors for projects from early-stage to GMP production, is working on enhancing intrinsic lentivirus characteristics and streamlining the process....

© GettyImages/metamorworks

Gamma Biosiences takes majority stake in Mirus Bio

By Jane Byrne

Gamma Biosciences has taken a controlling investment in Mirus Bio, an innovator and developer of biomimetic, cell-adaptive lipid-polymer nanocomplexes (LPNCs) for nucleic acid delivery based in Wisconsin in the US.

© GettyImages/metamorworks

Fujifilm expands its gene therapy drug CDMO business

By Jane Byrne

Fujifilm is boosting its gene therapy offering, taking the first steps to expand its viral vector contract development and manufacturing organization (CDMO) services to Europe, at the site of Fujifilm Diosynth Biotechnologies (FDB) in the North East of...

(Image: Getty/vchal)

Catalent bolsters Paragon through Novavax deal

By Vassia Barba

Aiming to boost the gene therapy development and manufacturing capabilities of Paragon, which Catalent acquired in April, the CDMO has agreed to acquire all of the gene therapy-related assets from Novavax, a late-stage vaccine developer.

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers